<DOC>
	<DOCNO>NCT01865799</DOCNO>
	<brief_summary>This prospective , 3-year observational study describe drug utilization uninfected individual ( UIs ) initiate emtricitabine ( FTC ) /tenofovir disoproxil fumarate ( TDF ) ( Truvada® ) pre-exposure prophylaxis ( PrEP ) indication . An electronic source pharmacy/medical encounter information use ass demographic characteristic subject prescribe FTC/TDF component prospective fashion . The data provider supply de-identified information regard visit/interaction subject health system diagnose medication UI prospectively retrospectively length time capture source select . 200 physician prescribe FTC/TDF PrEP indication sample source .</brief_summary>
	<brief_title>A Prospective , Observational , Drug Utilization Study Subjects Taking Truvada Pre-exposure Prophylaxis USA</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<criteria>Key Patient/ Uninfected Individual Adult ( sex/gender , include transgender ) ≥18 year old Taking FTC/TDF prescribe indication component Prescriber Possesses active health care professional license good standing , authority prescribe prescription medication , either independently ( eg , physician ) legally permissible arrangement prescribe physician supervision ( eg , Nurse Practitioner Physician Assistant ) Practice site within USA Having prescribe FTC/TDF PrEP indication Key There exclusion criterion individual prescribers Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>FTC/TDF</keyword>
	<keyword>PrEP</keyword>
	<keyword>Truvada</keyword>
	<keyword>Drug utilization</keyword>
</DOC>